Supha Pharmachem Begins Insolvency Process with Creditor Claims Exceeding ₹1,237 Crore

Total creditor claims filed against Supha Pharmachem Ltd. have surpassed ₹1,237 crore, with a substantial portion already admitted by the interim resolution professional.

Insolvency Process Underway

Supha Pharmachem Limited officially commenced its Corporate Insolvency Resolution Process (CIRP) on March 17, 2026, following an order from the National Company Law Tribunal (NCLT). The Interim Resolution Professional, Mr. Rajesh Jhunjhunwala, has taken charge of the company's affairs.

Creditors have filed claims totaling ₹1,237,511,620. Of this amount, ₹821,735,148 has been admitted, while ₹411,931,472 is currently under verification.

A significant challenge has emerged as the company's suspended directors are reportedly not cooperating with the Interim Resolution Professional. They have allegedly failed to provide necessary records and information, leading to the postponement of a scheduled board meeting and complicating the initial stages of the resolution process.

Why This Matters

The insolvency resolution process is a structured framework under India's Insolvency and Bankruptcy Code, 2016, designed to resolve a company's financial distress. The goal is to either revive the company through a viable resolution plan or, if unsuccessful, liquidate its assets.

When the insolvency process begins, the powers of the company's Board of Directors are suspended, and management control transfers to the Interim Resolution Professional. This significantly alters the company's governance and operational oversight.

The non-cooperation from suspended directors could impede the Interim Resolution Professional's ability to accurately assess the company's financial health and develop an effective resolution plan, potentially delaying or complicating the entire recovery effort.

Company Background

Supha Pharmachem, previously known as Remedium Lifecare Limited, was incorporated in 1988 and is based in Mumbai. The company operates in the pharmaceutical ingredients sector, primarily trading API intermediates and raw materials.

The company has faced financial difficulties in the past. In the fiscal year 2024-25, it encountered a non-compliance issue regarding its board composition, failing to meet SEBI's minimum member requirements.

The current insolvency process was initiated following a default of ₹7.47 crore to an operational creditor, Boston Ivy Healthcare Solution Private Limited, on November 7, 2023. This led to the NCLT order admitting the company into the resolution process.

Key Changes at Supha Pharmachem

• Management Control: Shareholders and the suspended Board of Directors have lost management control. The Interim Resolution Professional is now responsible for managing the company's affairs.
• Operational Management: The Interim Resolution Professional will oversee the company's day-to-day operations while working towards a resolution.
• Resolution Process: A formal process involving creditor claims, the formation of a Committee of Creditors, and the development of a resolution plan will now unfold.
• Future Outlook: The company's future depends on the success of the insolvency resolution process, which could lead to its revival or liquidation.

Key Risks in the Process

• Director Non-Cooperation: Continued failure of suspended directors to cooperate with the Interim Resolution Professional could significantly delay or obstruct the resolution process and the gathering of critical financial data.
• Resolution Plan Failure: If a viable resolution plan is not approved by the Committee of Creditors and the National Company Law Tribunal, the company may be directed for liquidation, involving the sale of its assets.
• Information Gaps: Lack of crucial financial data due to director non-cooperation can hinder the Interim Resolution Professional's accurate assessment of the company's true financial health.

Industry Context

Supha Pharmachem's trading-focused business model faces higher exposure to market volatility and competition compared to larger, integrated pharmaceutical manufacturers such as Sun Pharma or Divi's Labs. Companies with substantial manufacturing capabilities, like SRF or Aarti Industries, typically possess stronger market positions and greater financial resilience.

Other pharmaceutical firms, including Parental Drugs India and Orchid Pharma, have previously navigated insolvency resolution processes, with some eventually being acquired through these mechanisms.

Process Timeline and Metrics

• The insolvency resolution process typically aims for completion within 330 days, including extensions, as stipulated by the Insolvency and Bankruptcy Code, 2016.
• The default date that triggered the current process was November 7, 2023.

What to Watch Next

• First Committee of Creditors Meeting: The outcome of the Committee of Creditors meeting scheduled for April 14, 2026, will be critical for understanding the creditor body's direction.
• Director Cooperation: Any progress in securing cooperation from the suspended directors will be a key development.
• Claim Verification: Updates on the verification status of remaining creditor claims.
• Resolution Plan Development: Progress in formulating and evaluating potential plans for the company's revival or restructuring.
• National Company Law Tribunal Directives: Any further orders or directives issued by the National Company Law Tribunal.